Zobrazeno 1 - 10
of 124
pro vyhledávání: '"I. C. Henderson"'
Autor:
Angelo Raffaele Bianco, J. Carpenter, Rory Collins, M. Abeloff, H. Mouridsen, O. Abe, Gianni Bonadonna, J. Crowley, Aman U. Buzdar, R. Cooper, Rowan T. Chlebowski, F. Boccardo, Jack Cuzick, Michael Baum, D. Ahmann, I. C. Henderson, Marc Buyse, K. Andersen, P. Carbone
We sought information worldwide on mortality according to assigned treatment in all randomized trials that began before 1985 of adjuvant tamoxifen or cytotoxic therapy for early breast cancer (with or without regional lymph-node involvement). Coverag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ce8351bc4ab3fad6747af73b705dcb7
https://ora.ox.ac.uk/objects/uuid:b006d3f5-86f3-4aeb-84db-7eb9a977dc19
https://ora.ox.ac.uk/objects/uuid:b006d3f5-86f3-4aeb-84db-7eb9a977dc19
Autor:
C. Walter, D. J. Pendlington, V. King, J. K. Vis, G. Smith, I. C. Henderson, Keith Goulding, S. J. Groves, J. van Oostrum, Rachel Hine, Jules Pretty
Publikováno v:
International Journal of Agricultural Sustainability. 6:37-62
This review describes the establishment in 1997 of an agricultural sustainability initiative by the foods, home and personal care company, Unilever. It analyses the development and testing of a system of indicators used over several years on the comp
Autor:
Michael Crump, Paul G. Richardson, Gary L. Rosner, David D. Hurd, James J. Vredenburgh, Larry Norton, Constance Cirrincione, William P. Peters, Richard L. Schilsky, Elizabeth J. Shpall, Lawrence B. Marks, Michael W. Schuster, I. C. Henderson
Publikováno v:
Journal of Clinical Oncology. 23:2191-2200
Purpose The prognosis for women with primary breast cancer involving multiple axillary nodes remains poor. High-dose chemotherapy with stem-cell support produced promising results in initial clinical trials conducted at single institutions. Patients
Autor:
Joseph Aisner, Howard L. Parnes, S. L. Allen, Donald A. Berry, D. B. Duggan, Michael C. Perry, T. P. Szatrowski, Larry Norton, J. Abrams, I. C. Henderson, M. R. Cooper, Constance Cirrincione, E. Chuang
Publikováno v:
Journal of Clinical Oncology. 21:1819-1824
Purpose: To determine whether biochemical modulation with LV (leucovorin) enhances the efficacy of CAF (cyclophosphamide, doxorubicin, and fluorouracil) against metastatic breast cancer. Patients and Methods: Women with histologically confirmed stage
Autor:
Rebecca Gelman, Abram Recht, Patricia H. Hardenbergh, D Blanks, P Hauptman, Jules E. Harris, I. C. Henderson, Daniel F. Hayes, Charles L. Shapiro
Publikováno v:
Journal of Clinical Oncology. 16:3493-3501
PURPOSE To assess the cardiac effects of two different cumulative doses of adjuvant doxorubicin and radiation therapy (RT) in breast cancer patients. PATIENTS AND METHODS Two hundred ninety-nine breast cancer patients were prospectively randomized to
Autor:
Thomas J. Smith, Nicholas J. Robert, David Cella, M L Citron, I C Henderson, Kishan J. Pandya, M Grove-Conrad, Martin D. Abeloff, John H. Fetting, Diane L. Fairclough, C K Osborne, Richard Gray, K A Margolin
Publikováno v:
Journal of Clinical Oncology. 16:2382-2391
PURPOSE The Intergroup conducted this breast cancer adjuvant trial to compare an investigational 16-week regimen with cyclophosphamide, doxorubicin, and fluorouracil (5-FU; CAF). The 16-week regimen features greater doxorubicin and 5-FU dose-intensit
Autor:
Daniel F. Hayes, Harris, I. C. Henderson, Barbara Silver, Abram Recht, Lawrence N. Shulman, Steven E. Come, Rebecca Gelman
Publikováno v:
New England Journal of Medicine. 334:1356-1361
Patients with early-stage breast cancer who are at substantial risk for systemic metastases are increasingly treated with breast-conserving therapy and adjuvant chemotherapy. However, the optimal sequencing of chemotherapy and radiation therapy is no
Autor:
Paul Peter Rosen, Andrew D. Seidman, José Baselga, Debasish Tripathy, T. Twaddell, Nancy Sklarin, Christopher C. Benz, L. Dantis, I. C. Henderson, Larry Norton, John Mendelsohn, J. Moore, S. Baughman, Clifford A. Hudis
Publikováno v:
Journal of Clinical Oncology. 14:737-744
PURPOSE Breast cancer frequently overexpresses the product of the HER2 proto-oncogene, a 185-kd growth factor receptor (p185HER2). The recombinant humanized monoclonal antibody (rhuMAb) HER2 has high affinity for p185HER2 and inhibits the growth of b
Autor:
I C Henderson, K Wong
Publikováno v:
World Journal of Surgery. 18:98-111
Systemic treatment almost certainly prolongs the median survival of women with metastatic breast cancer, and it may prolong the survival of a small number of patients substantially. Even with conventional therapy, 10% or more patients may live into t
Autor:
Debasish Tripathy, I. C. Henderson
Publikováno v:
Current Opinion in Oncology. 4:1041-1050
Systemic therapy for operable breast cancer can delay the time to recurrence. Recurrence of breast cancer can follow a variable clinical course but will lead to death in virtually all cases. This delay is reflected in an accompanying improvement in o